Subtype
Lung Neuroendocrine Neoplasm
CI-CAN-00001096Explore in graph →
Non-malignant399 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001096Explore in graph →
Clinical trials
1,149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07153055 | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer(LOTS) | recruiting | Phase 1 / Phase 2 | 16 | Misty ShieldsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07508852 | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Peking University First HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07473128 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | recruiting | Phase 3 | 120 | Pharmacosmos A/SINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05257551 | Tempus Small Cell Lung Cancer Observational Study (Sculptor) | recruiting | — | 200 | Tempus AIINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06957314 | A Study of Hospital-at-Home for People Receiving Tarlatamab | recruiting | N/A | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07091305 | A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05419076 | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07267000 | EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER(ImmuEX) | recruiting | N/A | 50 | Medical University of GrazOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | recruiting | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | recruiting | Phase 2 | 37 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | recruiting | Phase 1 | 150 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC(RAISE) | recruiting | Phase 2 | 44 | ETOP IBCSG Partners FoundationNETWORK | 5 | May 29, 2026 | clinicaltrials |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | recruiting | Phase 2 | 280 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07583511 | Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study | recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05918302 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.(LEVEL) | recruiting | Phase 3 | 170 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | May 12, 2026 | clinicaltrials |
| NCT05363280 | Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment | recruiting | Phase 2 | 80 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT07296809 | SKB500 Combinations in Patients With Small Cell Lung Cancer | recruiting | Phase 2 | 80 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06217757 | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | recruiting | Phase 1 / Phase 2 | 45 | Sichuan UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07565532 | Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07249879 | This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. | recruiting | Phase 1 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05903092 | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer(MOZART) | recruiting | Phase 2 | 84 | Hirva MamdaniOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer | recruiting | Phase 1 | 100 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07243132 | Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)(LUNGEVITY) | recruiting | — | 1,000 | GFPC InvestigationOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06536868 | Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC | recruiting | Phase 2 | 40 | Second Hospital of Shanxi Medical UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07529145 | Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment | recruiting | — | 90 | Medical University of BialystokOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04919382 | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | recruiting | Phase 2 | 56 | Dwight OwenOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 386 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07510724 | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab(IKF-ReWoLuTe) | recruiting | — | 240 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Apr 3, 2026 | clinicaltrials |
| NCT06840704 | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer(Relief) | recruiting | Phase 3 | 121 | Hunan Cancer HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07015892 | Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial(ESCALADOR) | recruiting | Phase 3 | 300 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06424067 | Phase 2 Study of Fingolimod in Lung Cancers | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06769126 | Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | recruiting | Phase 2 | 900 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07055581 | Durvalumab as Consolidation for Patients LS-SCLC | recruiting | Phase 2 | 100 | Qian ChuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04170946 | Talazoparib and Thoracic RT for ES-SCLC(Talazoparib) | recruiting | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07010263 | A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy(AK112-311) | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05068232 | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | recruiting | Phase 2 | 49 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06719700 | Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07219251 | Engagement of Veterans With Lung Cancer(EVLC) | recruiting | N/A | 194 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07110103 | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC(JACKPOT38) | recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07434518 | A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC | recruiting | — | 500 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2026source: clinicaltrials